BiotechTube

GTX-102

Phase 3Active
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Angelman Syndrome

Conditions

Angelman Syndrome

Trial Timeline

Dec 3, 2024 → Nov 1, 2027

NCT ID
NCT06617429

About GTX-102

GTX-102 is a phase 3 stage product being developed by Ultragenyx Pharmaceutical for Angelman Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT06617429. Target conditions include Angelman Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (4)

NCT IDPhaseStatus
NCT07157254Phase 2Recruiting
NCT06617429Phase 3Active
NCT06415344Phase 3Recruiting
NCT04259281Phase 1/2Completed

Competing Products

9 competing products in Angelman Syndrome

See all competitors
ProductCompanyStageHype Score
RO7248824RochePhase 1
33
RO7248824RochePhase 1
33
AlogabatRochePhase 2
52
ION582Ionis PharmaceuticalsPhase 1/2
38
ION582 + PlaceboIonis PharmaceuticalsPhase 3
74
GTX-102Ultragenyx PharmaceuticalPhase 3
72
GTX-102Ultragenyx PharmaceuticalPhase 2
47
GTX-102Ultragenyx PharmaceuticalPhase 1/2
36
NNZ-2591Neuren PharmaceuticalsPhase 2
47

Other Products from Ultragenyx Pharmaceutical

Crysvita (burosumab-twza) TreatmentApproved
80
EvinacumabPhase 3
72
Adjuvant Immunomodulatory (IM) TherapyPhase 3
72
Oral prednisolone + Placebo for oral prednisolonePhase 3
72
TriheptanoinPhase 3
72